The FlashForward™ Consortium's mission is to continue research and build an evidence-based introduction of FLASH therapy using the ProBeam platform. Working groups in the FlashForward Consortium will help identify the preclinical study design for understanding this therapy; develop and share protocols that will enable a safe and quality clinical start for new users; and assist with regulatory and advocacy efforts.
The founding members of the FlashForward Consortium are:
- University of Maryland Department of Radiation Oncology
- Cincinnati Children's/UC Health Proton Therapy Center
- Danish Centre for Particle Therapy
- Holland Proton Therapy Centre
- New York Proton Center
- Penn Medicine
- The Christie Proton Therapy Centre
- University College London
- Proton International at the University of Alabama at Birmingham
- Emory Proton Therapy Center
- Paul Scherrer Institute
- Sylvester Comprehensive Cancer Center Proton Therapy
- VU University Medical Center Amsterdam
- South Florida Proton Therapy Institute
What is "FLASH" therapy?
FLASH therapy is a non-invasive treatment using an external beam delivered in high doses, at ultra-high speeds (less than 1 second), and administered in one to three sessions. This new therapy represents an exciting and potentially promising new direction in the treatment of cancer.
“We are very excited about the initial preclinical research that has been done on FLASH therapy and the potential for a major breakthrough in cancer care,” said Dee Khuntia, MD, chief medical officer, Varian. “Varian’s preclinical results have shown significantly reduced toxicities to healthy tissues while maintaining excellent tumour control and thereby enhancing the therapeutic ratio. We look forward to working closely with the members of the FlashForward Consortium and taking a big step forward in the fight against cancer.”
- Deepak “Dee” Khuntia, M.D.
Senior Vice President and Chief Medical Officer,
Varian Medical Systems